Rare Diseases
News
GETUG 13: Dose-dense chemo is new standard for poor-risk germ cell tumors
Major finding: At 3 years, the primary endpoint of progression-free survival in the dose-dense group was 59% vs.
Conference Coverage
Simple conditioning, GVHD prophylaxis yields good hematologic malignancy survival
Major finding: For patients with hematologic malignancies treated with busulfan/fludarabine conditioning, allogeneic bone marrow transplant, and...
News
FDA approves denosumab for giant cell tumors
Article
Benign metastasizing leiomyoma: ‘a sheep in wolf’s clothing’
Article
Malignant phyllodes tumor of the prostate and seminal vesicle: an unusual presentation
News
Gene alteration lowers bladder cancer risk
Major finding: A 0.77-fold reduced risk of bladder cancer was associated with a single nucleotide polymorphism (rs10759) found on the RGS4 gene....
Article
Plasmablastic lymphoma in the ileum
News
PET projects treatment response in adult Hodgkin's disease
Major Finding: Among patients with Hodgkin’s lymphoma whose PET scans were negative for residual disease following three cycles of ABVD...
News
Fewer Deaths with Tighter Hematocrit Target in Polycythemia Vera
Major Finding: In this study, 2.8% of patients treated to a hematocrit target of less than 45% experienced one or more events in a composite...
Conference Coverage
More Bevacizumab Trials to Report Outcomes in San Antonio
News
Tivantinib Shows Modest Benefit in Relapsed Liver Cancer
Major Finding: Median time to progression, the primary end point, was 6.9 weeks for patients randomized to tivantinib, compared with 6.0 weeks for...